The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reacti ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection by a health care professional.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Seventy-four percent of respondents unaware of FDA-approved treatments; 56% said these options had not been discussed by clinician.

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

HealthDay News — Prescribing medical cannabis to patients with chronic health conditions may improve health-related quality of life (HRQL), as well as some specific symptoms such as pain, fatigue, ...

Relevant risk for interaction seen with cardiac implantable electronic devices; no signs of cardiac damage seen during testing.